Delete

CoQ10 Shows Promise For Hearts

Suggested Veterinary Products

FOOTNOTES

1. Freeman LM and Rush JE.  Nutrition and cardiomyopathy:  lessons from spontaneous animal models.  Curr Heart Fail Rep.  2007;4(2):84-90.

2. Hamlin RL and Buffington CAT.  Nutrition and the heart.  Veterinary Clinics of North America:  Small Animal Practice.  1989;19(3):527-538.

3. Freeman LM.  Interventional nutrition for cardiac disease.  Clinical Techniques in Small Animal Practice.  1998;13(4):232-237.

4. Rocha M and Victor VM.  Targeting antioxidants to mitochondria and cardiovascular diseases:  the effects of mitoquinone.  Med Sci Monit.  2007;13(7):RA132-RA145.

5. Bolcal CC, Yildirim V, Doganci S, et al.  Do N-acetylcystein, ß-glucan, and coenzyme Q10 mollify myocardial ischemia-reperfusion injury?  The Heart Surgery Forum.  2007;10(3):E222-E227.

6. Bolcal CC, Yildirim V, Doganci S, et al.  Do N-acetylcystein, ß-glucan, and coenzyme Q10 mollify myocardial ischemia-reperfusion injury?  The Heart Surgery Forum.  2007;10(3):E222-E227.

7. Haas RH.  The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease.  Mitochondrion.  2007;7S:S136-S145.

8. Haas RH.  The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease.  Mitochondrion.  2007;7S:S136-S145.

9. Bolcal CC, Yildirim V, Doganci S, et al.  Do N-acetylcystein, ß-glucan, and coenzyme Q10 mollify myocardial ischemia-reperfusion injury?  The Heart Surgery Forum.  2007;10(3):E222-E227.

10. Pepe S, Marasco SF, Haas SJ, et al.  Coenzyme Q10 in cardiovascular disease.  Mitochondrion.  2007;7S:S154-S167.

11. Haas RH.  The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease.  Mitochondrion.  2007;7S:S136-S145.

12. DeFrancesco TC, Atkins CE, and Keene BW.  Myocardial infarction complicating management of congestive heart failure in a dog.  J Am Anim Hosp Assoc.  1996;32(1):68-72.

13. Driehys S, Van Winkle TJ, Sammarco CD, et al.  Myocardial infarction in dogs and cats:  37 cases (1985-1994).  J Am Vet Med Associ.  1998;213(10):1444-1448.

14. Tarnow I, Falk T, Tidholm A, et al.  Hemostatic biomarkers in dogs with chronic congestive heart failure.  J Vet Intern Med.  2007;21:451-457.

15. Lin CS, Liu CY, Sun YL, et al.  Alteration of endogenous antioxidant enzymes in naturally occurring hypertrophic cardiomyopathy.  Biochem Mol Biol Int.  1997;43(6):1253-1263.

16. Baumer AT, Flesch M, Wang X, et al.  Antioxidative enzymes in human hearts with idiopathic dilated cardiomyopathy.  J Mol Cell Cardiol.  2000;32(1):121-130.

17. Sam F, Kerstetter DL, Pimental DR, et al.  Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium.  J Card Fail.  2005;11(6):473-480.

18. Pepe S, Marasco SF, Haas SJ, et al.  Coenzyme Q10 in cardiovascular disease.  Mitochondrion.  2007;7S:S154-S167.

19. Pepe S, Marasco SF, Haas SJ, et al.  Coenzyme Q10 in cardiovascular disease.  Mitochondrion.  2007;7S:S154-S167.

20. Haas RH.  The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease.  Mitochondrion.  2007;7S:S136-S145.

21. Nukui K, Matsuoka Y, Yamagishi T, et al.  Safety assessment of PureSorb-Q ™40 in healthy subjects and serum coenzyme Q10 level in excessive dosing.  J Nutri Sci Vitamino.  2007;53:198-206.

22. Pepe S, Marasco SF, Haas SJ, et al.  Coenzyme Q10 in cardiovascular disease.  Mitochondrion.  2007;7S:S154-S167.

23. Shalansky S, Lynd L, Richardson K, et al.  Risk of warfarin-related bleeding events and supratherapeutic International Normalized Ratios associated with complementary and alternative medicine:  a longitudinal analysis.  Pharmacotherapy.  2007;27(9):1237-1247.

24. Zaghloul AA, Gurley B, Khan M, et al.  Bioavailability assessment of oral coenzyme Q10 formulations in dogs.  Drug Development and Industrial Pharmacy.  2002;28(10):1195-1200.

25. Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm. 2001 Jan 16;212(2):233-46.

26. Hathcock JN and Shao A.  Risk assessment for coenzyme Q10 (ubiquinone).  Regulatory Toxicology and Pharmacology.  2006;45:282-288. 

<HOME>

Leave a Comment

Comments

Your email address will not be published. Required fields are marked *